Biocryst Pharmaceuticals Q3 2026 Results: Net Income $37.9M, Up 193.9% YoY
BioCryst Pharmaceuticals reported 257,299,269 shares of common stock outstanding as of October 30, 2026. The filing highlights the commercialization of ORLADEYO, the strategic merger with Astria, and a shift toward prioritizing external innovation and clinical development of product candidates like navenibart.
- Key figure
- Net income $37.9M · +193.9% YoY